InvestSMART

Artrya Limited (ASX:AYA)

ALERT: Price-sensitive ASX Announcement for AYA
Current share price for AYA : $4.030 -1.38 (-25.51%)+
Announcement
Release
23 Jul 2026 8:30AM
Price at Release
$5.410
Full Release
download
Summary
Artrya Limited, an Australian medical technology company, has successfully launched its Salix® AI-powered cloud platform for coronary artery disease assessment at the Northeast Georgia Health System. The platform, now operational in one of NGHS's hospitals, generates revenue through subscriptions and per-scan fees. Artrya plans to roll out Salix® to other NGHS sites and intends further expansion with U.S. partners. The Salix® platform includes modules for anatomy and plaque assessment, with a coronary flow module pending FDA clearance.
Key Points
  • Artrya Limited's Salix® platform is live in Northeast Georgia Health System.
  • Salix® generates revenue through monthly subscription fees and per-scan fees.
  • The platform supports the diagnosis of coronary artery disease.
  • Salix® is expected to expand to all five hospitals in the NGHS network.
  • Artrya aims for similar deployments with other U.S. foundation partners.
  • The Salix® Coronary Flow module awaits FDA clearance for clinical use.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.